These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 29298817)

  • 21. The PDCD4/miR-21 pathway in medullary thyroid carcinoma.
    Pennelli G; Galuppini F; Barollo S; Cavedon E; Bertazza L; Fassan M; Guzzardo V; Pelizzo MR; Rugge M; Mian C
    Hum Pathol; 2015 Jan; 46(1):50-7. PubMed ID: 25316501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer.
    Fallahi P; Ferrari SM; Baldini E; Biricotti M; Ulisse S; Materazzi G; Miccoli P; Antonelli A
    Expert Rev Anticancer Ther; 2016 Nov; 16(11):1109-1118. PubMed ID: 27650489
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.
    Robinson BG; Paz-Ares L; Krebs A; Vasselli J; Haddad R
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2664-71. PubMed ID: 20371662
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circulating miR-26b-5p and miR-451a as diagnostic biomarkers in medullary thyroid carcinoma patients.
    Besharat ZM; Trocchianesi S; Verrienti A; Ciampi R; Cantara S; Romei C; Sabato C; Noviello TMR; Po A; Citarella A; Caruso FP; Panariello I; Gianno F; Carpino G; Gaudio E; Chiacchiarini M; Masuelli L; Sponziello M; Pecce V; Ramone T; Maino F; Dotta F; Ceccarelli M; Pezzullo L; Durante C; Castagna MG; Elisei R; Ferretti E
    J Endocrinol Invest; 2023 Dec; 46(12):2583-2599. PubMed ID: 37286863
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment.
    Werner RA; Schmid JS; Muegge DO; Lückerath K; Higuchi T; Hänscheid H; Grelle I; Reiners C; Herrmann K; Buck AK; Lapa C
    Medicine (Baltimore); 2015 Nov; 94(45):e2016. PubMed ID: 26559299
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vandetanib and the management of advanced medullary thyroid cancer.
    Campbell MJ; Seib CD; Gosnell J
    Curr Opin Oncol; 2013 Jan; 25(1):39-43. PubMed ID: 23202050
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vandetanib therapy in medullary thyroid cancer.
    Grabowski P; Briest F; Baum RP; Zaknun JJ; Kulkarni HR; Zeitz M; Hörsch D
    Drugs Today (Barc); 2012 Nov; 48(11):723-33. PubMed ID: 23170308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multilayer OMIC Data in Medullary Thyroid Carcinoma Identifies the STAT3 Pathway as a Potential Therapeutic Target in
    Mancikova V; Montero-Conde C; Perales-Paton J; Fernandez A; Santacana M; Jodkowska K; Inglada-Pérez L; Castelblanco E; Borrego S; Encinas M; Matias-Guiu X; Fraga M; Robledo M
    Clin Cancer Res; 2017 Mar; 23(5):1334-1345. PubMed ID: 27620278
    [No Abstract]   [Full Text] [Related]  

  • 29. Validation of miRNAs as diagnostic and prognostic biomarkers, and possible therapeutic targets in medullary thyroid cancers.
    Mondin A; Bertazza L; Barollo S; Pedron MC; Manso J; Piva I; Basso D; Merante Boschin I; Iacobone M; Pezzani R; Mian C; Censi S
    Front Endocrinol (Lausanne); 2023; 14():1151583. PubMed ID: 37361540
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ATF4 Targets RET for Degradation and Is a Candidate Tumor Suppressor Gene in Medullary Thyroid Cancer.
    Bagheri-Yarmand R; Williams MD; Grubbs EG; Gagel RF
    J Clin Endocrinol Metab; 2017 Mar; 102(3):933-941. PubMed ID: 27935748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer.
    Del Rivero J; Edgerly M; Ward J; Madan RA; Balasubramaniam S; Fojo T; Gramza AW
    Oncologist; 2019 Jan; 24(1):16-e14. PubMed ID: 30297385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative Proteomics Analysis of Sporadic Medullary Thyroid Cancer Reveals FN1 as a Potential Novel Candidate Prognostic Biomarker.
    Zhan S; Li J; Wang T; Ge W
    Oncologist; 2018 Dec; 23(12):1415-1425. PubMed ID: 29739896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.
    Fox E; Widemann BC; Chuk MK; Marcus L; Aikin A; Whitcomb PO; Merino MJ; Lodish M; Dombi E; Steinberg SM; Wells SA; Balis FM
    Clin Cancer Res; 2013 Aug; 19(15):4239-48. PubMed ID: 23766359
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RET Kinase-Regulated MicroRNA-153-3p Improves Therapeutic Efficacy in Medullary Thyroid Carcinoma.
    Joo LJS; Weiss J; Gill AJ; Clifton-Bligh R; Brahmbhatt H; MacDiarmid JA; Gild ML; Robinson BG; Zhao JT; Sidhu SB
    Thyroid; 2019 Jun; 29(6):830-844. PubMed ID: 30929576
    [No Abstract]   [Full Text] [Related]  

  • 35. Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study.
    Subbiah V; Hu MI; Mansfield AS; Taylor MH; Schuler M; Zhu VW; Hadoux J; Curigliano G; Wirth L; Gainor JF; Alonso G; Adkins D; Godbert Y; Ahn MJ; Cassier PA; Cho BC; Lin CC; Zalutskaya A; Barata T; Trask P; Scalori A; Bordogna W; Heinzmann S; Brose MS
    Thyroid; 2024 Jan; 34(1):26-40. PubMed ID: 38009200
    [No Abstract]   [Full Text] [Related]  

  • 36. A miRNA signature associated with human metastatic medullary thyroid carcinoma.
    Santarpia L; Calin GA; Adam L; Ye L; Fusco A; Giunti S; Thaller C; Paladini L; Zhang X; Jimenez C; Trimarchi F; El-Naggar AK; Gagel RF
    Endocr Relat Cancer; 2013 Dec; 20(6):809-23. PubMed ID: 24127332
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Utilizing the circulating tumor markers in diagnosis and management of medullary thyroid cancer.
    Zarkesh M; Arab N; Tavangar SM; Nozhat Z; Fanaei SM; Hedayati M
    Pathol Res Pract; 2022 Jan; 229():153694. PubMed ID: 34929598
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analytical and clinical validation of pairwise microRNA expression analysis to identify medullary thyroid cancer in thyroid fine-needle aspiration samples.
    Ciarletto AM; Narick C; Malchoff CD; Massoll NA; Labourier E; Haugh K; Mireskandari A; Finkelstein SD; Kumar G
    Cancer Cytopathol; 2021 Mar; 129(3):239-249. PubMed ID: 33017868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SAFETY AND TOLERABILITY OF VANDETANIB IN JAPANESE PATIENTS WITH MEDULLARY THYROID CANCER: A PHASE I/II OPEN-LABEL STUDY.
    Uchino K; Komoda M; Tomomatsu J; Okamoto T; Horiuchi K; Tsuji A; Ito Y; Todo T; Rito K; Takahashi S
    Endocr Pract; 2017 Feb; 23(2):149-156. PubMed ID: 27819766
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changes in circulating microRNAs after radiochemotherapy in head and neck cancer patients.
    Summerer I; Niyazi M; Unger K; Pitea A; Zangen V; Hess J; Atkinson MJ; Belka C; Moertl S; Zitzelsberger H
    Radiat Oncol; 2013 Dec; 8():296. PubMed ID: 24373621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.